<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 获取免费报告) 的股价在周四交易中下跌了 6.8%。该公司的股价最低曾达到 5.67 美元，最后交易价为 5.6280 美元。在午盘交易中，共成交了 1,886,479 股，较平均交易量 2,872,656 股下降了 34%。该股票此前收盘价为 6.04 美元。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>分析师仍看好的三大高动量公司</li>
</ul>
<p>CMPX 已成为几份研究报告的主题。Cantor Fitzgerald 于 12 月 3 日星期三在一份研究报告中开始覆盖 Compass Therapeutics。他们对该股票给予了 “增持” 评级。花旗集团在 12 月 3 日星期三的研究报告中开始覆盖 Compass Therapeutics 的股票。他们对该公司给予了 “跑赢大盘” 的评级。Leerink Partners 在 11 月 26 日星期三的研究报告中将 Compass Therapeutics 的股票评级提升至 “强力买入”。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Compass Therapeutics 股票的 “卖出（d-）” 评级。最后，Raymond James Financial 在 1 月 6 日星期二的研究报告中重新发布了 “跑赢大盘” 评级，并设定了 9.00 美元的目标价。一位股票研究分析师对该股票给予了强力买入评级，十四位分析师给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 12.23 美元。</p>
<p><strong>查看我们关于 CMPX 的最新报告</strong></p>
<h2>Compass Therapeutics 股票下跌 4.2%</h2>
<p>该股票的市值为 10.3 亿美元，市盈率为-12.86，贝塔值为 1.45。该公司的 50 日简单移动平均线为 5.13 美元，200 日简单移动平均线为 3.99 美元。</p>
<p>Compass Therapeutics (NASDAQ:CMPX - 获取免费报告) 最近于 11 月 5 日星期三发布了其财报。该公司报告每股收益（EPS）为-0.08 美元，超出分析师的共识预期-0.14 美元，超出幅度为 0.06 美元。整体来看，分析师预计 Compass Therapeutics, Inc. 在本年度将发布-0.36 美元的每股收益。</p>
<h2>对 Compass Therapeutics 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Suvretta Capital Management LLC 在第三季度将其在 Compass Therapeutics 的股份增加了 97.2%。Suvretta Capital Management LLC 现在拥有该公司 14,101,159 股股票，价值 49,354,000 美元，此前在该期间内购买了额外的 6,951,666 股。Vivo Capital LLC 在第三季度将其在 Compass Therapeutics 的持仓增加了 57.9%。Vivo Capital LLC 现在拥有该公司 9,545,466 股股票，价值 33,409,000 美元，此前在上个季度购买了额外的 3,502,000 股。先锋集团在第三季度将其在 Compass Therapeutics 的持仓增加了 45.6%。先锋集团现在拥有该公司 7,062,799 股股票，价值 24,720,000 美元，此前在该期间内购买了额外的 2,212,794 股。Adage Capital Partners GP L.L.C. 在第二季度将其在 Compass Therapeutics 的持仓增加了 11.3%。Adage Capital Partners GP L.L.C. 现在拥有该公司 4,424,868 股股票，价值 11,505,000 美元，此前在该期间内购买了额外的 449,868 股。最后，Millennium Management LLC 在第三季度将其在 Compass Therapeutics 的持仓增加了 280.4%。Millennium Management LLC 现在拥有该公司 3,237,572 股股票，价值 11,332,000 美元，此前在上个季度购买了额外的 2,386,367 股。机构投资者和对冲基金持有该公司 68.43% 的股份。</p>
<h2>关于 Compass Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
<p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα 通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的举措</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
<p>在您考虑 Compass Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPX

<p>Compass Therapeutics（纳斯达克代码：CMPX）股价下跌 6.8%，至 5.6280 美元，交易量较平均水平下降 34%。分析师的评级意见不一，Cantor Fitzgerald 和花旗集团分别给予 “增持” 和 “跑赢大盘” 的评级，而 Weiss Ratings 则维持 “卖出” 评级。该公司的市值为 10.3 亿美元，市场共识评级为 “适度买入”，目标价为 12.23 美元。机构投资者持有 68.43% 的股份，多个对冲基金的持股比例显著增加。该公司专注于免疫肿瘤治疗，报告的每股收益为（-0.08 美元），超出预期</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price traded down 6.8% during trading on Thursday . The company traded as low as $5.67 and last traded at $5.6280. 1,886,479 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 2,872,656 shares. The stock had previously closed at $6.04.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 获取免费报告) 的股价在周四交易中下跌了 6.8%。该公司的股价最低曾达到 5.67 美元，最后交易价为 5.6280 美元。在午盘交易中，共成交了 1,886,479 股，较平均交易量 2,872,656 股下降了 34%。该股票此前收盘价为 6.04 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师仍看好的三大高动量公司</li>
</ul>
</div><p>CMPX has been the topic of several research reports. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an &#34;overweight&#34; rating on the stock. Citigroup assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an &#34;outperform&#34; rating for the company. Leerink Partnrs raised shares of Compass Therapeutics to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 26th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Finally, Raymond James Financial reissued an &#34;outperform&#34; rating and set a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $12.23.</p>
<div class="lb-trans"><p>CMPX 已成为几份研究报告的主题。Cantor Fitzgerald 于 12 月 3 日星期三在一份研究报告中开始覆盖 Compass Therapeutics。他们对该股票给予了 “增持” 评级。花旗集团在 12 月 3 日星期三的研究报告中开始覆盖 Compass Therapeutics 的股票。他们对该公司给予了 “跑赢大盘” 的评级。Leerink Partners 在 11 月 26 日星期三的研究报告中将 Compass Therapeutics 的股票评级提升至 “强力买入”。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Compass Therapeutics 股票的 “卖出（d-）” 评级。最后，Raymond James Financial 在 1 月 6 日星期二的研究报告中重新发布了 “跑赢大盘” 评级，并设定了 9.00 美元的目标价。一位股票研究分析师对该股票给予了强力买入评级，十四位分析师给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 12.23 美元。</p>
</div><p><strong>Check Out Our Latest Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CMPX 的最新报告</strong></p>
</div><h2>Compass Therapeutics Stock Down 4.2%</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股票下跌 4.2%</h2>
</div><p>The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -12.86 and a beta of 1.45. The company's fifty day simple moving average is $5.13 and its 200 day simple moving average is $3.99.</p>
<div class="lb-trans"><p>该股票的市值为 10.3 亿美元，市盈率为-12.86，贝塔值为 1.45。该公司的 50 日简单移动平均线为 5.13 美元，200 日简单移动平均线为 3.99 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. As a group, analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>Compass Therapeutics (NASDAQ:CMPX - 获取免费报告) 最近于 11 月 5 日星期三发布了其财报。该公司报告每股收益（EPS）为-0.08 美元，超出分析师的共识预期-0.14 美元，超出幅度为 0.06 美元。整体来看，分析师预计 Compass Therapeutics, Inc. 在本年度将发布-0.36 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Compass Therapeutics</h2>
<div class="lb-trans"><h2>对 Compass Therapeutics 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its stake in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company's stock worth $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC grew its holdings in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Vanguard Group Inc. increased its position in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company's stock worth $24,720,000 after buying an additional 2,212,794 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company's stock worth $11,505,000 after buying an additional 449,868 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Compass Therapeutics by 280.4% during the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company's stock worth $11,332,000 after buying an additional 2,386,367 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Suvretta Capital Management LLC 在第三季度将其在 Compass Therapeutics 的股份增加了 97.2%。Suvretta Capital Management LLC 现在拥有该公司 14,101,159 股股票，价值 49,354,000 美元，此前在该期间内购买了额外的 6,951,666 股。Vivo Capital LLC 在第三季度将其在 Compass Therapeutics 的持仓增加了 57.9%。Vivo Capital LLC 现在拥有该公司 9,545,466 股股票，价值 33,409,000 美元，此前在上个季度购买了额外的 3,502,000 股。先锋集团在第三季度将其在 Compass Therapeutics 的持仓增加了 45.6%。先锋集团现在拥有该公司 7,062,799 股股票，价值 24,720,000 美元，此前在该期间内购买了额外的 2,212,794 股。Adage Capital Partners GP L.L.C. 在第二季度将其在 Compass Therapeutics 的持仓增加了 11.3%。Adage Capital Partners GP L.L.C. 现在拥有该公司 4,424,868 股股票，价值 11,505,000 美元，此前在该期间内购买了额外的 449,868 股。最后，Millennium Management LLC 在第三季度将其在 Compass Therapeutics 的持仓增加了 280.4%。Millennium Management LLC 现在拥有该公司 3,237,572 股股票，价值 11,332,000 美元，此前在上个季度购买了额外的 2,386,367 股。机构投资者和对冲基金持有该公司 68.43% 的股份。</p>
</div><h2>About Compass Therapeutics</h2>
<div class="lb-trans"><h2>关于 Compass Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα 通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的举措</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Compass Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Therapeutics (NASDAQ:CMPX) 股价下跌 6.8% - 现在是卖出的时候吗？